RESISTENTIA PHARMACEUTICALS
Resistentia Pharmaceuticals, a biopharmaceutical company, develops immunotherapeutic products for allergic asthma and inflammatory disorders. It provides Immunoglobulin E for allergic reactions, including asthma, rhinitis, and dermatitis; and C5a for the treatment of inflammatory conditions, such as rheumatoid arthritis, asthma, and multiple sclerosis. Resistentia Pharmaceuticals AB was founded in 1998 and is based in Uppsala, Sweden.
RESISTENTIA PHARMACEUTICALS
Industry:
Biotechnology Health Care Medical Device Therapeutics
Founded:
1998-01-01
Address:
Uppsala, Uppsala Lan, Sweden
Country:
Sweden
Status:
Active
Total Funding:
13.96 M USD
Similar Organizations
Epicyte Pharmaceuticals
Epicyte Pharmaceutical is focused on development therapeutic monoclonal antibodies for cancer, infectious and inflammatory diseases.
Investors List
Innovations Kapital
Innovations Kapital investment in Series C - Resistentia Pharmaceuticals
Industrifonden
Industrifonden investment in Series C - Resistentia Pharmaceuticals
GSK
GSK investment in Series C - Resistentia Pharmaceuticals
BankInvest Biomedical Venture
BankInvest Biomedical Venture investment in Series C - Resistentia Pharmaceuticals
HealthCap
HealthCap investment in Series C - Resistentia Pharmaceuticals
More informations about "Resistentia Pharmaceuticals"
Resistentia Pharmaceuticals AB - Uppsala, Sweden - bionity.com
Nov 10, 2006 Building on over 10 years of academic research, Resistentia was founded in 1998. Since then, the Company has developed an industrial organization consisting of 25 people, โฆSee details»
Resistentia Pharmaceuticals AB - VentureRadar
" Resistentia Pharmaceuticals AB, a biotechnology company founded in 1998, developing an allergy vaccine with human as well as veterinary applications. The method may offer new hope โฆSee details»
Resistentia Pharmaceuticals - Funding, Financials, Valuation
Resistentia Pharmaceuticals develops immunotherapeutic products for allergic asthma and inflammatory disorders. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. โฆSee details»
Resistentia Pharmaceuticals - LinkedIn
Resistentia Pharmaceuticals AB is a biotechnology company focusing on the development of innovative immunotherapies. The Companyโs lead project is an immunotherapy for the โฆSee details»
Resistentia Pharmaceuticals AB: Drug pipelines, Patents, Clinical ...
Explore Resistentia Pharmaceuticals AB with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, and 1 literature.See details»
Resistentia Pharmaceuticals AB:Company Profile & Technical โฆ
Resistentia Pharmaceuticals AB is headquartered in Sweden . Resistentia Pharmaceuticals AB was founded in 1998. Resistentia Pharmaceuticals AB has a total of 53 patents . Related โฆSee details»
Resistentia Pharmaceuticals AB - Uppsala, Suède - bionity.com
Resistentia Pharmaceuticals AB est une société de biotechnologie qui se concentre sur le développement d'immunothérapies innovantes. Le projet principal de la société est une โฆSee details»
Organization | Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Report issue. For profit Phase 2. Founded: Uppsala Sweden ... Organization Overview. First Clinical Trial. 2007 NCT00439621. First Marketed Drug. None ...See details»
Resistentia Pharmaceuticals AB - BioCentury Company Profiles
Apr 23, 2007 Resistentia Pharmaceuticals AB - BioCentury Company Profiles for the biopharma industrySee details»
Resistentia Pharmaceuticals - Products, Competitors, Financials ...
Resistentia Pharmaceuticals is a biotechnology company focusing on the development of innovative immunotherapies. Use the CB Insights Platform to explore Resistentia โฆSee details»
Resistentia Pharmaceuticals - Drug pipelines, Patents, Clinical trials ...
Jul 7, 2023 Explore Resistentia Pharmaceuticals with its drug pipeline, therapeutic area, technology platform, , Drug:RP-01.See details»
Resistentia Pharmaceuticals Initiates Phase II Clinical Testing of ...
Apr 19, 2007 Resistentia Pharmaceuticals is a privately held biopharmaceutical company developing innovative immunotherapies that target allergic asthma and allergic rhinitis as well โฆSee details»
Resistentia Pharmaceuticals AB - VentureRadar
BioInvent Sweden Listed BioInvent is a research-based pharmaceutical company that focuses on developing antibody drugs. The company is currently running drug projects within the areas of โฆSee details»
Resistentia Pharmaceuticals Raises EUR 11 Million - BioSpace
Sep 26, 2006 About Resistentia Pharmaceuticals Resistentia Pharmaceuticals AB is a Swedish privately held biotech company developing innovative immunotherapies that target allergy and โฆSee details»
Resistentia Pharmaceuticals AB (Resistentia Pharmaceuticals AB)
ไบ่งฃResistentia Pharmaceuticals AB (Resistentia Pharmaceuticals AB)ๅ ฌๅธ็่ฏ็ฉ็ฎก็บฟ๏ผๆฒป็้ขๅ๏ผๆๆฏๅนณๅฐ๏ผไปฅๅๅฎ็2้กนไธดๅบ่ฏ้ชใSee details»
Resistentia Pharmaceuticals AB Sweden Corporation
Resistentia Pharmaceuticals AB Sweden Corporation has 0 patent litigation cases (0 cases currently active) - 0 patents asserted - 0 cases as a plaintiff - 0 cases as a defendantSee details»
Resistentia Pharmaceuticals funding & investors - Tracxn
Feb 9, 2025 Resistentia Pharmaceuticals has raised a total funding of $14M over 1 round from 5 investors. Investors include SR One, Healthcap and 3 others. Their latest funding round was of โฆSee details»
Resistentia Pharmaceuticals AB, Sweden corporatin - US Patent โฆ
Resistentia Pharmaceuticals AB, Sweden corporatin - *profile and listings may contain filings by different individuals or companies with the same name. Review application materials to โฆSee details»
Biovitrum wins contract to manufacture pharmaceutical substance โฆ
Nov 10, 2006 Biovitrum has entered an agreement with the Uppsala-based biotech company Resistentia Pharmaceuticals AB for process development and manufacturing of the โฆSee details»
Novartis receives FDA accelerated approval for Vanrafia® โฆ
6 days ago Ad hoc announcement pursuant to Art. 53 LR. Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS โฆSee details»